Closer look at TAILORx confirms lack of chemo benefit regardless of race or ethnicity

(ECOG-ACRIN Cancer Research Group) Before TAILORx, there was uncertainty about treatment for women with hormone receptor-positive, HER2-negative, node-negative breast cancer and a score of 11-25 on a tumor gene test. The trial was designed to address this question and provides a definitive answer: no benefit from chemotherapy for women over 50 with a score of 11-25; 50 years old or younger with a score of 11-15; and any age with a score of 0-10.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news